Octave Announces Publication of Analytical Validation Study Results in Nature Communications More

Get in Touch

Octave at MSMilan2023!

Wednesday, Oct. 11 – Friday, Oct. 13
Milan, Italy

As the curtain falls on MSMilan2023, our commitment to create a dynamic, longitudinal perspective of patients with multiple sclerosis (MS) using insights from the Octave Precision Care Solution reaches new corners of the world.

Explore Octave’s announcements, presentations and each of the 9 posters presented at the 9th Joint ECTRIMS-ACTRIMS Meeting!

Product Theatre

Delivering on the Promise of Precision Medicine: Lessons Learned Through Real-World Clinical Experience

Friday, Oct. 13

The discussion highlighted real-world clinical examples of how the Octave Precision Care Solution is being used to deliver the benefits of precision medicine for MS.

Key Speakers included:

  • Barry Singer, MD, Director and Founder of The MS Center for Innovations in Care at Missouri Baptist Medical Center and Associate Professor of Clinical Neurology at Washington University School of Medicine
  • Mitzi Joi Williams, MD, FAAN, Medical Director, Joi Life Wellness Neurology Group
  • Julie Burnham, DO, President/Owner Michigan Neurology
  • Michael Sy, MD, PhD, Associate Professor of Clinical Neurology, Department of Neurology, University of California, Irvine

Octave Product Theatre at MSMilan2023.

Brain Exchange

Optimization of Advanced Imaging Biomarkers for Objective Decision-Support in MS: From Research to the Real World

Friday, Oct. 13

The conversation spotlighted how imaging biomarkers are being used for objective decision-support in the real world with the Octave Precision Care Solution, which includes enhanced MRI analytics and protocols.

Key Speakers included:

  • Jennifer Graves, MD, PhD, MAS, Professor of Neurosciences, Director of the UCSD Neuroimmunology Research Program, Director of the Rady Children’s Pediatric MS Center
  • Kelly Leyden, Senior Product Lead, Octave
Company News & Media Coverage

Octave Presents Data Highlighting Application and Impact of its Precision Care Solution at MSMilan2023

New data demonstrates a wide range of findings deploying Octave’s Precision Care Solution, revealing important insights about disease behavior in both research and real-world settings – bringing precision medicine to the forefront.

Business Wire Read Article

Advancing Precision Medicine for Multiple Sclerosis: Mitzi Joi Williams, MD

Neurology Live Watch Video

Barry Singer, MD, on Recent Strides in the Treatment and Management of Multiple Sclerosis

Neurology Live NEUROVOICES Read Article

Reviewing the Utilization of Serum Biomarker Tests for Diagnosing Multiple Sclerosis: William Kilgo, MD

Neurology Live Watch Video

Subscribe to Stay In Touch

Posters

  1. Biology – Serum Biomarkers of Clinical and Radiographic Disease Progression in Multiple Sclerosis
  2. Biology – Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population
  3. Biology – CXCL-13, CXCL-9 and IL-12 cerebrospinal fluid levels predict higher disease activity and are associated with intrathecal IgM synthesis in multiple sclerosis
  4. Biology – Compartmentalized complement activation is associated with cytokines CXCL-13, CXCL-9, Il-12b and paramagnetic rim lesions in multiple sclerosis
  5. Imaging – Disagreement Among Neuroradiologists Detecting Change in Multiple Sclerosis Disease Activity
  6. Imaging – Interpretable Thalamic Volume Charts in Multiple Sclerosis
  7. Biology – Disease Activity Score and Disease Pathway Scores Measured Using the MSDA Test are Significantly Reduced Prior to the Week 48 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies
  8. Biology – Lower arterial cerebral blood flow is associated with worse neuroinflammation and immunomodulation composite proteomic scores
  9. Biology – Performance Comparison of a Multi-Protein Multiple Sclerosis Disease Activity Test for Blood Serum Samples That Were Collected Before Versus After the MRI Scan

© 2024 Octave Bioscience, Inc | 1440 O’Brien Drive, Suite B, Menlo Park, CA 94025 

Connect with us